Patent Law Weblog
recent posts
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
- United States Files Statement of Interest in Patent Infringement Proceedings
about
Month: February 2011
-
By James DeGiulio — Medicis and Q-Med Settle Restylane Dispute with Genzyme Genzyme has agreed to drop its infringement suit with Medicis regarding the cosmetic injection product Restylane in exchange for a lump sum payment from Q-Med. In October 2010, Genzyme brought suit in the U.S. District Court for the District of Massachusetts against Medicis,…
-
By Kevin E. Noonan — The rift that has arisen between the U.S. Patent and Trademark Office and the Justice Department over the question of patent-eligibility for isolated genes seems to be continuing. Last Thursday, the Acting Solicitor General sent a letter to the Federal Circuit, requesting to opportunity to present oral argument to the Court…
-
By Kevin E. Noonan — Last Wednesday, the U.S. Patent and Trademark Office promulgated "Supplementary Examination Guidelines for Determining Compliance with 35 U.S.C. 112 and for Treatment of Related Issues" (76 Fed. Reg. 7162). The Guidelines, which take effect immediately and apply to all pending applications, "are intended to assist United States Patent and Trademark…
-
By Donald Zuhn — On February 4, the U.S. Patent and Trademark Office and European Patent Office announced that the two offices had reached agreement on the principles of a new joint patent classification system known as the Cooperative Patent Classification (CPC). The desire to develop a joint classification system was first announced last fall…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Novartis Pharmaceuticals Corp. et al. v. Mylan Pharmaceuticals Inc. et al.1:11-cv-00127; filed February 10, 2011 in the District Court of Delaware • Plaintiffs: Novartis Pharmaceuticals Corp.; Novartis AG• Defendants: Mylan Pharmaceuticals Inc.; Mylan Inc. Infringement…
-
February 16-17, 2011 – Life Sciences Collaborative Agreements and Acquisitions*** (American Conference Institute) – New York, NY February 16-17, 2011 – Biotech & Pharmaceutical Patenting (IBC Legal) – Munich, Germany March 16-17, 2011 – FDA Boot Camp*** (American Conference Institute) – New York, NY ***Patent Docs is a media partner of this conference or CLE
-
By James DeGiulio — Abbott Fails to Stay Patent Dispute with Wyeth over Stents Despite pending reexaminations over the patents-in-suit, Abbott Laboratories was unsuccessful in its attempt to stay litigation with Wyeth over patents for drug-coated stents. On September 22, 2009, Wyeth filed suit against Abbott in the U.S. District Court for the District of…
-
By Kevin E. Noonan — A number of groups have responded to the Senate Judiciary Committee vote to approve the Patent Reform Act of 2011 (see "Judiciary Committee Votes on Patent Reform Bill"). The Biotechnology Industry Organization (BIO), in a press release from President and CEO Jim Greenwood the day after the vote, praised Senators…
-
By Donald Zuhn — With the help of Patent Docs readers, we have been trying to collect copies of all of the briefs that have been filed in the Association of Molecular Pathology v. U.S. Patent and Trademark Office ("Myriad") case and make them available on our site. Of the thirty amicus briefs that have…
-
By James DeGiulio — Last year, we reported on the revival of the therapeutic potential of gene therapy, after the technique hibernated for years due to questions of safety and inefficient gene delivery (see "Gene Therapy Experiencing a Revival"). The revival continues with the announcement of a new gene therapy clinical trial initiated by San…
Patent Docs 